ICON plc (ICLR)
ICLR trades on Nasdaq in Health Care, Biotechnology: Commercial Physical & Biological Resarch. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1060955/000162828026038487/0001628280-26-038487-index.htm. Net income: SEC 20-F (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | ICLR on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Commercial Physical & Biological Resarch |
| Country | Ireland |
| IPO year | 1998 |
| SEC CIK | 0001060955 |
| SEC industry code | Services-Commercial Physical & Biological Research |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $8.3B |
| Net income | $229.3M |
| Operating income | $442.8M |
| Net margin | 2.8% |
| Operating margin | 5.4% |
| Revenue growth | +0.8% |
| Cash | $647.3M |
| Total assets | $16.3B |
| P/E (computed) | 63.9× |
| P/S (computed) | 1.8× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-05-27 |
| Cash and burn | $647.3M cash; operating cash flow $259.1M a quarter. | Report 2025-12-31 |
| Shares outstanding | 76,567,325 (2025-12-31); 80,756,860 a year earlier; 81,723,555 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | KPMG, Dublin, Ireland | PCAOB Form AP 2026-06-24 |
| Late filings, 12 months | 1 NT notice | NT 20-F 2026-05-01 |
| Insider trades, 12 months | Bought $0, sold $3.6M on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | $8.3B | $229.3M | $1.0B | $647.3M | $2.9B | $8.3B | 20-F 2026-05-27 |
| FY 2024 2024-12-31 | $8.2B | $739.1M | $1.3B | $538.8M | $3.4B | $8.2B | 20-F 2026-05-27 |
| FY 2023 2023-12-31 | $8.1B | $554.2M | $1.2B | $378.1M | $3.8B | $8.1B | 20-F 2026-05-27 |
| FY 2022 2022-12-31 | $7.7B | $505.3M | $563.3M | $288.8M | $4.7B | $7.7B | 20-F 2025-02-21 |
| FY 2021 2021-12-31 | $5.5B | $153.2M | $829.1M | $752.2M | $5.5B | $5.5B | 20-F 2024-02-23 |
| FY 2020 2020-12-31 | $2.8B | $332.3M | $568.0M | $840.3M | $348.5M | $2.8B | 20-F 2023-02-24 |
| FY 2019 2019-12-31 | $2.8B | $374.0M | $412.5M | $520.3M | No debt tags | $2.8B | 20-F 2022-03-01 |
| FY 2018 2018-12-31 | $2.6B | $322.7M | $268.6M | $395.9M | No debt tags | $2.6B | 20-F 2021-02-24 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document | 424B5 | 2024-05-02 |
| Latest annual report | 20-F | 2026-05-27 |
| Latest quarterly / interim | 6-K | 2026-11-10 |
Source: SEC EDGAR submissions feed, 845 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.9% |
| 1 month | +18.4% |
| 3 months | +16.2% |
| Year to date | +6.8% |
| 1 year | +19.1% |
| From 52-week high | -9.7% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Commercial Physical & Biological Resarch
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| CRL | Charles River Laboratories International Inc. | $335.52 | -0.72% | $16.1B |
| MEDP | Medpace Holdings Inc. | $648.20 | -0.88% | $18.1B |
| INCY | Incyte Corp. | $120.27 | -0.58% | $24.5B |
| IQV | IQVIA Holdings Inc. | $264.73 | -0.15% | $43.6B |
| ABSI | Absci Corporation | $7.47 | -11.54% | $1.3B |
| OABI | OmniAb Inc. | $4.89 | -0.41% | $713.3M |
| NRC | NRC Health | $26.33 | -0.87% | $558.8M |
| MXCT | MaxCyte Inc. | $1.18 | -0.84% | $121.8M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier